Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has announced a significant milestone in the development of its lead drug candidate, ONC010, by advancing kilogram-scale manufacturing activities for the B4 precursor component. The company reported the successful production and isolation of approximately 952 grams of B4 material through its collaboration with Dalton Pharma Services. This achievement supports future formulation development, Good Manufacturing Practice (GMP) production, and planned clinical studies for ONC010, a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology designed to target solid tumors.
The manufacturing milestone strengthens Onco-Innovations' integrated development strategy and lays the groundwork for establishing a scalable production process to ensure a reliable supply of the drug candidate for clinical trials. The company emphasized that this progress is critical for advancing ONC010 toward regulatory submissions and eventual commercialization. PNKP inhibitors represent a novel approach in oncology, potentially enhancing the effectiveness of DNA-damaging therapies by inhibiting DNA repair mechanisms in cancer cells.
In addition to the manufacturing update, Onco-Innovations announced the engagement of InvestorBrandNetwork (IBN) to provide market awareness, corporate communications, and digital media services through September 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 for these services and intends to apply an unused US$80,000 balance returned from a prior market awareness engagement toward the consideration. This move is expected to enhance visibility among investors and stakeholders as the company progresses toward clinical development.
The implications of this manufacturing milestone are significant for Onco-Innovations and the broader oncology field. By demonstrating the ability to produce B4 material at kilogram scale, the company reduces the risk of supply chain bottlenecks that often delay early-stage clinical trials. This achievement also positions ONC010 for potential investigational new drug (IND)-enabling studies and first-in-human trials. For patients, the advancement of PNKP inhibitors offers hope for more effective treatments against solid tumors, particularly those resistant to conventional therapies. For the industry, Onco-Innovations' progress underscores the growing feasibility of nanoparticle-based drug delivery systems in oncology.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a focus on oncology. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. More information is available at https://oncoinnovations.com/. The full press release can be accessed at https://ibn.fm/BbWHd.
